Streetbeat News

Regulatory

MTEM

Molecular Templates announced that the FDA has removed the partial clinical hold on its Phase 1 clinical trial for MT-0169, allowing the company to focus on extramedullary myeloma.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 12:00 pm

PYPL

PayPal has filed a U.S. patent application (#20230169587) for multi-layer artificial intelligence models aimed at progressive predictions during data pipeline management. This technology could enhance PayPal's data processing capabilities and improve its services.

Portfolio Pulse from Charles Gross

June 01, 2023 | 11:45 am

VQS

VIQ Solutions (NASDAQ:VQS) has filed two provisional patent applications with the USPTO for methods related to training and automated selection of domain-specific language models, aiming to improve documentation accuracy and usability for various organizations.

Portfolio Pulse from Charles Gross

June 01, 2023 | 11:39 am

SNSE

Sensei Biotherapeutics announced the first patient dosed in a Phase 1/2 clinical trial of SNS-101, a conditionally active VISTA-blocking antibody, for the treatment of advanced solid tumors. SNS-101 is designed to selectively block the immune checkpoint VISTA in the tumor microenvironment.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 11:33 am

FSR

Fisker Ocean Extreme has received an EPA Certificate of Conformity and a California Air Resources Board Executive Order, approving it for sale and delivery in the US.

Portfolio Pulse from Charles Gross

June 01, 2023 | 11:11 am

CLSD

Clearside Biomedical has opened enrollment for its ODYSSEY Phase 2b clinical trial of CLS-AX in Wet AMD. The trial is a randomized, double-masked, parallel-group, active-controlled, multi-center study with a duration of 36 weeks.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 11:11 am

TSLA

Elon Musk concluded his first visit to China in three years, meeting with Foreign Minister Qin Gang, industry and commerce ministers, and visiting Tesla's Shanghai factory. Musk discussed Tesla's expansion and advancement in China during the trip.

Portfolio Pulse from Anan Ashraf

June 01, 2023 | 11:09 am

AMRN

Amarin's partner EddingPharm has received regulatory approval for Vascepa (Icosapent Ethyl) in mainland China. This approval will allow the drug to be marketed and sold in the region.

Portfolio Pulse from Benzinga Newsdesk

June 01, 2023 | 10:03 am

AZN

AstraZeneca has announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development program, which included the Phase IIb/III INTREPID trial in Crohn's disease and the Phase II EXPEDITION trial in ulcerative colitis. The decision follows a review of the development timeline and the evolving competitive landscape, with no safety concerns identified.

Portfolio Pulse from Charles Gross

June 01, 2023 | 9:13 am

AZN

MRK

AstraZeneca and MSD's Lynparza has been approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer. The drug will be used in combination with abiraterone and prednisone or prednisolone.

Portfolio Pulse from Charles Gross

June 01, 2023 | 9:11 am